Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Paolicchi

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Critical Reviews in Oncology/Hematology|November 25, 2011
Polycomb genes and cancer: time for clinical application?Francesco Crea, Elisa Paolicchi, Victor E Marquez, et al.
Critical Reviews in Oncology/Hematology|December 26, 2012
Histone lysine demethylases in breast cancerElisa Paolicchi, Francesco Crea, William L Farrar, et al.
Oncotarget|February 10, 2016
Targeting hypoxic response for cancer therapyElisa Paolicchi, Federica Gemignani, Marija Krstic-Demonacos, et al.
Biomarkers in Medicine|March 28, 2012
An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jawFabio La Ferla, Elisa Paolicchi, Francesco Crea, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|September 30, 2011
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategiesFrancesco Crea, Stefania Nobili, Elisa Paolicchi, et al.
Molecular Cancer Therapeutics|May 25, 2012
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cellsAmir Avan, Francesco Crea, Elisa Paolicchi, et al.
Oncology Letters|November 2, 2013
A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinomaElisa Paolicchi, Paola Pacetti, Elisa Giovannetti, et al.
Oncology|September 1, 2016
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer PatientsElisa Paolicchi, Caterina Vivaldi, Veronica De Gregorio, et al.
Investigational New Drugs|December 10, 2020
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesotheliomaIrene Dell'Anno, Sarah A Martin, Marcella Barbarino, et al.
BMC Cancer|November 11, 2015
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancerLorenzo Fornaro, Pinuccia Faviana, Veronica De Gregorio, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Critical Reviews in Oncology/Hematology|November 25, 2011
Polycomb genes and cancer: time for clinical application?Francesco Crea, Elisa Paolicchi, Victor E Marquez, et al.
Critical Reviews in Oncology/Hematology|December 26, 2012
Histone lysine demethylases in breast cancerElisa Paolicchi, Francesco Crea, William L Farrar, et al.
Oncotarget|February 10, 2016
Targeting hypoxic response for cancer therapyElisa Paolicchi, Federica Gemignani, Marija Krstic-Demonacos, et al.
Biomarkers in Medicine|March 28, 2012
An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jawFabio La Ferla, Elisa Paolicchi, Francesco Crea, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|September 30, 2011
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategiesFrancesco Crea, Stefania Nobili, Elisa Paolicchi, et al.
Molecular Cancer Therapeutics|May 25, 2012
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cellsAmir Avan, Francesco Crea, Elisa Paolicchi, et al.
Oncology Letters|November 2, 2013
A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinomaElisa Paolicchi, Paola Pacetti, Elisa Giovannetti, et al.
Oncology|September 1, 2016
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer PatientsElisa Paolicchi, Caterina Vivaldi, Veronica De Gregorio, et al.
Investigational New Drugs|December 10, 2020
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesotheliomaIrene Dell'Anno, Sarah A Martin, Marcella Barbarino, et al.
BMC Cancer|November 11, 2015
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancerLorenzo Fornaro, Pinuccia Faviana, Veronica De Gregorio, et al.
Pageof 2